HRP20202073T1 - Derivati n-(fenilsulfonil)benzamida kao bcl-2 inhibitori - Google Patents
Derivati n-(fenilsulfonil)benzamida kao bcl-2 inhibitori Download PDFInfo
- Publication number
- HRP20202073T1 HRP20202073T1 HRP20202073TT HRP20202073T HRP20202073T1 HR P20202073 T1 HRP20202073 T1 HR P20202073T1 HR P20202073T T HRP20202073T T HR P20202073TT HR P20202073 T HRP20202073 T HR P20202073T HR P20202073 T1 HRP20202073 T1 HR P20202073T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- pharmaceutically acceptable
- cancer
- solvate
- image
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662371504P | 2016-08-05 | 2016-08-05 | |
| US201762454101P | 2017-02-03 | 2017-02-03 | |
| EP17754889.8A EP3494115B1 (en) | 2016-08-05 | 2017-08-04 | N-(phenylsulfonyl)benzamide derivatives as bcl-2 inhibitors |
| PCT/US2017/045428 WO2018027097A1 (en) | 2016-08-05 | 2017-08-04 | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20202073T1 true HRP20202073T1 (hr) | 2021-02-19 |
Family
ID=59677319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20202073TT HRP20202073T1 (hr) | 2016-08-05 | 2017-08-04 | Derivati n-(fenilsulfonil)benzamida kao bcl-2 inhibitori |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10829488B2 (OSRAM) |
| EP (3) | EP3494115B1 (OSRAM) |
| JP (2) | JP6651180B2 (OSRAM) |
| KR (2) | KR102429704B1 (OSRAM) |
| CN (2) | CN110483501B (OSRAM) |
| AU (2) | AU2017305508B2 (OSRAM) |
| CA (1) | CA3031419C (OSRAM) |
| CY (1) | CY1123859T1 (OSRAM) |
| DK (1) | DK3494115T3 (OSRAM) |
| ES (1) | ES2849959T3 (OSRAM) |
| HR (1) | HRP20202073T1 (OSRAM) |
| HU (1) | HUE053414T2 (OSRAM) |
| IL (2) | IL264059B (OSRAM) |
| LT (1) | LT3494115T (OSRAM) |
| MX (2) | MX381588B (OSRAM) |
| MY (1) | MY199409A (OSRAM) |
| PE (1) | PE20190711A1 (OSRAM) |
| PH (1) | PH12019500231A1 (OSRAM) |
| PT (1) | PT3494115T (OSRAM) |
| RS (1) | RS61821B1 (OSRAM) |
| RU (2) | RU2722560C1 (OSRAM) |
| SA (1) | SA519401020B1 (OSRAM) |
| SG (2) | SG10201913643YA (OSRAM) |
| SI (1) | SI3494115T1 (OSRAM) |
| SM (1) | SMT202100025T1 (OSRAM) |
| WO (1) | WO2018027097A1 (OSRAM) |
| ZA (2) | ZA201900240B (OSRAM) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11001582B2 (en) * | 2016-03-10 | 2021-05-11 | Assia Chemical Industries Ltd. | Solid state forms of Venetoclax and processes for preparation of Venetoclax |
| LT3494115T (lt) * | 2016-08-05 | 2021-01-25 | The Regents Of The University Of Michigan | N-(fenilsulfonil)benzamido dariniai kaip bcl-2 inhibitoriai |
| WO2018127130A1 (en) | 2017-01-07 | 2018-07-12 | Shanghai Fochon Pharmaceutical Co., Ltd. | Compounds as bcl-2-selective apoptosis-inducing agents |
| PT3612531T (pt) * | 2017-04-18 | 2022-10-04 | Shanghai Fochon Pharmaceutical Co Ltd | Agentes indutores de apoptose |
| US11420968B2 (en) | 2018-04-29 | 2022-08-23 | Beigene, Ltd. | Bcl-2 inhibitors |
| TWI752335B (zh) * | 2018-07-31 | 2022-01-11 | 大陸商蘇州亞盛藥業有限公司 | Bcl-2抑制劑與MDM2抑制劑的組合產品及其在預防及/或治療疾病中的用途 |
| UA125241C2 (uk) * | 2018-07-31 | 2022-02-02 | Есентейдж Фарма (Сучжоу) Ко., Лтд. | СИНЕРГІЧНИЙ ПРОТИПУХЛИННИЙ ЕФЕКТ ІНГІБІТОРА Bcl-2 В ПОЄДНАННІ З РИТУКСИМАБОМ ТА/АБО БЕНДАМУСТИНОМ АБО ІНГІБІТОРА Bcl-2 В ПОЄДНАННІ З CHOP |
| CN110772521A (zh) | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| AU2019314819A1 (en) * | 2018-07-31 | 2020-10-22 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
| CN111214471B (zh) * | 2018-11-23 | 2021-04-02 | 苏州亚盛药业有限公司 | 药物组合物及其用途 |
| TWI770503B (zh) * | 2019-05-13 | 2022-07-11 | 大陸商蘇州亞盛藥業有限公司 | 用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物 |
| TW202114692A (zh) * | 2019-07-02 | 2021-04-16 | 大陸商蘇州亞盛藥業有限公司 | 一種含有mTOR抑制劑的藥物組合及其應用 |
| AU2020321068A1 (en) * | 2019-07-31 | 2021-03-18 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
| WO2021104442A1 (en) * | 2019-11-27 | 2021-06-03 | Ascentage Pharma (Suzhou) Co., Ltd. | Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway |
| TWI772992B (zh) * | 2019-12-03 | 2022-08-01 | 大陸商蘇州亞盛藥業有限公司 | 作為bcl-2抑制劑的n-(苯基磺醯基)苯甲醯胺及相關化合物 |
| CN118542872A (zh) * | 2019-12-04 | 2024-08-27 | 苏州亚盛药业有限公司 | 药物组合及其用途 |
| JP7142173B2 (ja) | 2019-12-06 | 2022-09-26 | ロクソ オンコロジー， インコーポレイテッド | ブルトン型チロシンキナーゼ阻害剤の投薬 |
| WO2021175321A1 (en) | 2020-03-06 | 2021-09-10 | Ascentage Pharma (Suzhou) Co., Ltd. | Crystalline forms or amorphous forms of n- (phenyl sulfonyl) benzamide compounds or its salts or solvates |
| US20230128137A1 (en) * | 2020-03-12 | 2023-04-27 | Medshine Discovery Inc. | Benzo five-membered cyclic compound |
| IL296582A (en) | 2020-04-15 | 2022-11-01 | Beigene Ltd | bcl-2 inhibitor |
| WO2021227763A1 (en) * | 2020-05-14 | 2021-11-18 | Ascentage Pharma (Suzhou) Co., Ltd. | Hplc analysis method for n- (phenylsulfonyl) benzamide compound |
| WO2022002178A1 (en) * | 2020-07-01 | 2022-01-06 | Ascentage Pharma (Suzhou) Co., Ltd. | Methods for synthesizing n-(phenylsulfonyl)benzamide compounds and intermediates thereof |
| CN111537654B (zh) * | 2020-07-07 | 2020-11-10 | 上海亚盛医药科技有限公司 | N-(苯基磺酰基)苯甲酰胺化合物的hplc分析方法 |
| KR20230038231A (ko) * | 2020-07-10 | 2023-03-17 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 술포닐벤즈아미드 유도체 및 이의 접합체, 이의 제조 방법 및 이의 용도 |
| CN114057728A (zh) * | 2020-08-06 | 2022-02-18 | 北京诺诚健华医药科技有限公司 | 作为bcl-2抑制剂的杂环化合物 |
| US20230398110A1 (en) * | 2020-08-21 | 2023-12-14 | Ascentage Pharma (Suzhou) Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| CN114073707A (zh) * | 2020-08-21 | 2022-02-22 | 苏州亚盛药业有限公司 | 治疗系统性红斑狼疮的组合物和方法 |
| WO2022111558A1 (en) * | 2020-11-25 | 2022-06-02 | Ascentage Pharma (Suzhou) Co., Ltd. | Solid dispersion, pharmaceutical preparations, preparation method, and application thereof |
| CN114681458B (zh) * | 2020-12-28 | 2023-07-18 | 苏州亚盛药业有限公司 | 治疗多发性硬化症的方法 |
| CN114835704B (zh) * | 2021-02-01 | 2023-10-27 | 苏州亚盛药业有限公司 | 作为bcl-2抑制剂的磺酰基苯甲酰胺衍生物 |
| US20250319183A1 (en) | 2021-04-07 | 2025-10-16 | David Avigan | Compositions and methods for the treatment of cancer |
| JP2024528174A (ja) | 2021-08-02 | 2024-07-26 | アセンテージ ファーマ（スーチョウ）カンパニー，リミティド | 医薬組合せおよびその使用 |
| KR20240135747A (ko) * | 2021-12-06 | 2024-09-12 | 항저우 힐젠 테라퓨틱스 컴퍼니 리미티드 | 항-세포사멸 단백질 bcl-2 억제제, 약학적 조성물 및 이의 응용 |
| CN115260191B (zh) * | 2022-09-29 | 2022-12-27 | 上海睿跃生物科技有限公司 | 哌啶类化合物及其制备方法和应用 |
| EP4421075A1 (en) * | 2023-02-27 | 2024-08-28 | KRKA, d.d., Novo mesto | Process for the preparation of venetoclax and intermediates used therein |
| WO2024184233A1 (en) | 2023-03-03 | 2024-09-12 | Ionctura Sa | Combination of roginolisib and bcl-2 inhibitor in the treatment of haematological malignancy |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1021343A (en) | 1912-01-17 | 1912-03-26 | M A N Mfg Company | Locking-clamp. |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US7767684B2 (en) * | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| WO2008030836A2 (en) | 2006-09-05 | 2008-03-13 | Abbott Laboratories | Bcl inhibitors treating platelet excess |
| AU2007329458A1 (en) | 2006-12-04 | 2008-06-12 | Abbott Laboratories | Companion diagnostic assays for cancer therapy |
| UA108193C2 (uk) * | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| CA2744711C (en) | 2008-12-05 | 2017-06-27 | Abbott Laboratories | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| AU2010204555B2 (en) | 2009-01-19 | 2013-03-07 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| JP2012517241A (ja) | 2009-02-11 | 2012-08-02 | アボット・ラボラトリーズ | Ｂｃｌ−２ファミリー阻害剤耐性腫瘍及び癌を有する被験者を同定、分類及びモニターするための方法及び組成物 |
| US8546399B2 (en) * | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| PE20120345A1 (es) | 2009-05-26 | 2012-05-17 | Abbvie Bahamas Ltd | Derivados de 2-(1h-pirrolo[2,3-b]piridin-5-iloxi)-n-fenilsulfonilbenzamida como inhibidores de proteinas anti-apoptoticas |
| TWI520960B (zh) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| NZ608274A (en) | 2010-10-29 | 2015-05-29 | Abbvie Inc | Solid dispersions containing an apoptosis-inducing agent |
| SG190361A1 (en) | 2010-11-23 | 2013-06-28 | Abbvie Inc | Salts and crystalline forms of an apoptosis-inducing agent |
| MY165884A (en) | 2010-11-23 | 2018-05-18 | Abbvie Ireland Unlimited Co | Methods of treatment using selective bcl-2 inhibitors |
| JP6960912B2 (ja) | 2015-12-30 | 2021-11-05 | デックスコム・インコーポレーテッド | 感度プロファイルに基づく留置センサの工場校正または不完全校正のためのシステム及び方法 |
| LT3494115T (lt) | 2016-08-05 | 2021-01-25 | The Regents Of The University Of Michigan | N-(fenilsulfonil)benzamido dariniai kaip bcl-2 inhibitoriai |
-
2017
- 2017-08-04 LT LTEP17754889.8T patent/LT3494115T/lt unknown
- 2017-08-04 PE PE2019000335A patent/PE20190711A1/es unknown
- 2017-08-04 EP EP17754889.8A patent/EP3494115B1/en active Active
- 2017-08-04 RU RU2019105721A patent/RU2722560C1/ru active
- 2017-08-04 SI SI201730535T patent/SI3494115T1/sl unknown
- 2017-08-04 HU HUE17754889A patent/HUE053414T2/hu unknown
- 2017-08-04 US US16/317,056 patent/US10829488B2/en active Active
- 2017-08-04 RS RS20201599A patent/RS61821B1/sr unknown
- 2017-08-04 MX MX2019001391A patent/MX381588B/es unknown
- 2017-08-04 EP EP19184604.7A patent/EP3569601B1/en active Active
- 2017-08-04 RU RU2020114660A patent/RU2744358C2/ru active
- 2017-08-04 PT PT177548898T patent/PT3494115T/pt unknown
- 2017-08-04 ES ES17754889T patent/ES2849959T3/es active Active
- 2017-08-04 CN CN201910626474.XA patent/CN110483501B/zh active Active
- 2017-08-04 SG SG10201913643YA patent/SG10201913643YA/en unknown
- 2017-08-04 KR KR1020217026744A patent/KR102429704B1/ko active Active
- 2017-08-04 AU AU2017305508A patent/AU2017305508B2/en active Active
- 2017-08-04 MY MYPI2019000239A patent/MY199409A/en unknown
- 2017-08-04 HR HRP20202073TT patent/HRP20202073T1/hr unknown
- 2017-08-04 KR KR1020197002744A patent/KR102376764B1/ko active Active
- 2017-08-04 SM SM20210025T patent/SMT202100025T1/it unknown
- 2017-08-04 SG SG11201900135YA patent/SG11201900135YA/en unknown
- 2017-08-04 CN CN201780035965.6A patent/CN109311871B/zh active Active
- 2017-08-04 WO PCT/US2017/045428 patent/WO2018027097A1/en not_active Ceased
- 2017-08-04 CA CA3031419A patent/CA3031419C/en active Active
- 2017-08-04 JP JP2019506191A patent/JP6651180B2/ja active Active
- 2017-08-04 DK DK17754889.8T patent/DK3494115T3/da active
- 2017-08-04 EP EP22179906.7A patent/EP4129999A1/en active Pending
-
2018
- 2018-08-01 US US16/051,816 patent/US10221174B2/en active Active
-
2019
- 2019-01-02 IL IL264059A patent/IL264059B/en active IP Right Grant
- 2019-01-14 ZA ZA2019/00240A patent/ZA201900240B/en unknown
- 2019-01-31 PH PH12019500231A patent/PH12019500231A1/en unknown
- 2019-01-31 MX MX2020013014A patent/MX2020013014A/es unknown
- 2019-02-04 SA SA519401020A patent/SA519401020B1/ar unknown
- 2019-07-23 JP JP2019135624A patent/JP7205903B2/ja active Active
- 2019-12-19 ZA ZA2019/08466A patent/ZA201908466B/en unknown
-
2020
- 2020-09-17 US US17/023,426 patent/US11718613B2/en active Active
-
2021
- 2021-01-15 CY CY20211100032T patent/CY1123859T1/el unknown
- 2021-04-06 AU AU2021202113A patent/AU2021202113B2/en active Active
- 2021-04-06 IL IL282099A patent/IL282099B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20202073T1 (hr) | Derivati n-(fenilsulfonil)benzamida kao bcl-2 inhibitori | |
| HRP20201681T1 (hr) | Inhibitor aurora a kinaze | |
| HRP20230400T1 (hr) | Benzilamino supstituirani piridopirimidinoni i derivati kao inhibitori sos1 | |
| HRP20210212T1 (hr) | Triciklični spoj kao antikancerogeni agensi | |
| MX2020013817A (es) | Compuestos de naftiridinona sustituidos utiles como activadores de celulas t. | |
| ME02805B (me) | Inhibitori cdc7 | |
| HRP20220258T1 (hr) | Sastavi 1,2,4-oksadiazola i tiadiazola kao imunomodulatora | |
| HRP20180158T1 (hr) | Spojevi biarilamida kao inhibitori kinaze | |
| HRP20250119T1 (hr) | Kdm1a inhibitor i njegova primjena u terapiji | |
| HRP20250250T1 (hr) | Derivati 7‑benzil‑4‑(2‑metilbenzil)‑2,4,6,7,8,9‑heksahidroimidazo[1,2‑a]pirido[3,4‑e] pirimidin‑5(1h)‑ona, njihove soli i njihova upotreba u terapiji | |
| MX382331B (es) | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3f] isoquinolina útiles en el tratamiento del cáncer. | |
| HRP20150952T1 (hr) | Određeni triazolopirazini, njihovi pripravci i postupci njihove upotrebe | |
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| TN2018000119A1 (en) | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer | |
| ME02470B (me) | Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom | |
| BR112012027743A2 (pt) | ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas | |
| HRP20131081T1 (hr) | Kombinirane terapije koje sadrže hinoksalin inhibitor p13k-alfa za uporabu u lijeäśenju kancera | |
| EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
| HRP20210319T1 (hr) | Kombinacije inhibitora fgfr i inhibitora igf1r | |
| HRP20201264T1 (hr) | Prolijekovi gemcitabina | |
| PH12018500377A1 (en) | Novel annelated benzamides | |
| SA518390920B1 (ar) | مركبات فينوكسي أسيتاميد معالجة بإضافة حلقة | |
| PH12015502632A1 (en) | Cxcr7 receptor modulators | |
| HRP20150530T1 (hr) | Spojevi korisni za inhibiranje chk1 | |
| HRP20210537T1 (hr) | Upotreba inhibitora faktora induciranog hipoksijom |